Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of JMT108 in advanced melanoma and genitourinary tumors
CTR20254735Phase 2Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Dec 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of JMT108 in melanoma, Genitourinary Neoplasm, sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Dec 2025; status: active.
02
Drugs
JMT108
03
Conditions
melanomaGenitourinary Neoplasm
Beyond the preview
Go deeper on CTR20254735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254735.